Artelo Biosciences (ARTL) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
17 Jul, 2026Opening remarks and agenda
Meeting commenced with introductions of directors, auditors, and legal counsel present virtually.
Outlined the agenda: formal business, voting on proposals, and a Q&A session.
Confirmed compliance with bylaws and Nevada law, and explained the voting process for the meeting.
Board and executive committee updates
Three Class III director nominees—Gregory R. Reyes, Tamara A. Favorito, and Gregory D. Gorgas—were nominated for re-election to serve until the 2029 Annual Meeting.
Shareholder proposals
Proposal to elect three Class III directors to serve until 2029.
Proposal to amend articles of incorporation to increase authorized common stock from 166,666,667 to 500 million.
Proposal to approve issuance of more than 20% of outstanding common stock under an equity purchase agreement.
Latest events from Artelo Biosciences
- Shareholders urged to vote before July 17, 2026, to ensure quorum and efficient meeting conduct.ARTL
Proxy filing16 Jul 2026 - Shareholders can vote on key proposals at the July 17, 2026, annual meeting.ARTL
Proxy filing16 Jul 2026 - Shareholders will vote on director elections, share authorization, and a major equity issuance.ARTL
Proxy filing2 Jul 2026 - Multiple clinical milestones expected in the next 18 months across a diverse therapeutic pipeline.ARTL
H.C. Wainwright 26th Annual Global Investment Conference 202430 Jun 2026 - Shareholders will vote on director elections, a large share increase, and a major equity issuance.ARTL
Proxy filing22 Jun 2026 - Lead drug candidates advance in cancer, pain, and anxiety with strong safety and efficacy data.ARTL
Corporate presentation5 Jun 2026 - Vote on director elections and a major increase in authorized shares at the 2026 annual meeting.ARTL
Proxy filing5 Jun 2026 - Shareholders will vote on director elections and a major increase in authorized common stock.ARTL
Proxy filing5 Jun 2026 - Lead drug candidates show strong progress in major markets with robust safety and efficacy data.ARTL
Corporate presentation26 May 2026